- July 14-18, 2019
ISB presented posters on "A computer Model that simulates the effect of Tau antibodies on the inter-cellular spread of Tau",
"Using an ADAS-Cog Calibrated QSP Neuronal network model to explore the impact of tau mutation on action potential propagation" and
"A computer Model of oligomeric tau axonal transport and interaction with endogenous tau" all at the Alzheimer Association International Conference, Los Angeles, CA
- March 10-14, 2019
At the pre-conference course on "Applications of AI in Drug Discovery and Development" ISB gave a faculty presentation "From Big Data to Smart Data. How to augment human intelligence".
ISB presented "TURNING THE TIDE OF FAILED CNS TRIALS. USING QUANTITATIVE SYSTEMS PHARMACOLOGY-BASED MODELING OF INDIVIDUAL PATIENTS TO SUPPORT CLINICAL TRIAL DESIGN" at the Molecular Med Tri-Conference Bio-IT West, San Francisco, CA
- Feb 23, 2019
ISB gave webinar "Turning the Tide of Failed CNS Trials. Using Quantitative Systems Pharmacology to Support CNS Research & Development" for the C-Path Cosortium
- Dec 11, 2018
ISB contributed to "MODELING MEETS EXPERIMENTS. THE ELECTROPHYSIOLOGICAL CONSEQUENCES OF THE FTD V337M TAU MUTATION" at the NYAS Symposium on "Beyond Amyloid; new approaches in AD", New York
- Nov 11-14, 2018
ISB presented poster on "WHEN COMPUTER MODELING MEETS EXPERIMENTS. STUDYING THE ELECTROPHYSIOLOGICAL CONSEQUENCES OF THE FTD V337M TAU MUTATION" at the International Conference of Fronto-temporal Dementia, Sydney, Australia
- Oct 7-10, 2018
Hugo Geerts, CSO, launched the QSP CNS (Quantitative Systems Pharmacology in CNS diseases) workgroup as co-chairman with the oral presentation "QUANTITATIVE SYSTEMS PHARMACOLOGY APPLICATIONS IN CENTRAL NERVOUS SYSTEMS DISORDERS" at the American Conference on Pharmacometrics, San Diego, CA. The workgroup is tied to NeuroCoP and QSP Special Interest Groups which are part of the ISoP organization. Purpose is to drive the acceptance of advanced mechanistic based QSP modeling as a tool for supporting the Drug Discovery and Development Operation.
- July 20-25, 2018
Hugo Geerts gave talk on "MAPTA (MODELING ALLIANCE FOR SYSTEMS PHARMACOLOGY IN TAUOPATHIES). MODELING THE IMPACT OF TAU ON HYPEREXCITABILITY IN MCI" at the Alzheimer Association International Conference in Chicago, IL. ISB also presented posters on "MAPTA (MODELING ALLIANCE FOR SYSTEMS PHARMACOLOGY IN TAUOPATHIES). UNEXPECTED FINDINGS WITH A MODEL FOR ANTIBODY MEDIATED TAU CLEARING" and "REVISITING FAILED CLINICAL TRIALS. APPLICATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY TO THE IMPACT OF COMEDICATIONS, GENOTYPES AND AMYLOID STATUS ON SEROTONIN MODULATORS".
- June 17-22, 2018
ISB presented poster on "Why do so many amyloid trials fail? Analysis using Quantitative Systems Pharmacology platform" at the Keystone meeting on Advances in Neurodegenerative Disease, Keystone, CO
- June 14, 2018
ISB presented poster on "Using Quantitative Systems Pharmacology for re-purposing drugs for neuropsychiatric symptoms in Alzheimer's Disease" at the Neuropsychiatric Symptoms in Alzheimer's Disease, New York, NY
- May 24-26, 2018
Hugo Geerts, CSO gave the Keynote Lecture on "Towards the Virtual Patient. Developing Predictive Models for CNS Drug Discovery and Development with Quantitative Systems Pharmacology" at the 25th Human Animal Bridging Society, Tsukuba Japan
- May 15, 2018
Cohen Veterans Biosciences and ISB organized the third Workshop on MAPTA (Modeling Alliance for systems Pharmacologies in TAuopathies), Washington, DC. The purpose of the alliance is to integrate available knowledge about neurobiology and clinical data on tau in an actionable computer model to (1) better understand the biology of tau and its role in tauopathies, (2) help validating new druggable targets for therapeutic intervention and (3) use this tool for drug repurposing.
- April 4-8, 2018
ISB presented posters on "Personalized Medicine. Estimating the Impact of Genotypes on Antipsychotic Efficacy Using Quantitative Systems Pharmacology" and "Quantitative Systems Pharmacology as an Alternative to Chlorpromazine Equivalents. Predictive Validation from a Cris Database Experiment" at the Schizophrenia International Research Society Conference, Firenze, Italy
- Feb 26-28, 2018
ISB was an innovation partner at the AI Pharma Innovation: Drug Discovery Summit 2018. Hugo Geerts presented "The In Silico Biosciences Quantitative Systems Pharmacology (QSP) Platform as the Next Step in the Big Data AI Value Chain in CNS", in the Enhancing Drug Discovery Productivity Session, San Francisco, CA
- Feb 20-22, 2018
ISB presented poster on "Why do Amyloid-Modulating Clinical Trials Fail in Alzheimer's Disease? A Critical Analysis Using Quantitative Systems Pharmacology" at the International Society for CNS Clinical Trials and Methodology 14th Annual Scientific Meeting, Washington, DC
- Jan 15-18, 2018
ISB contributed on "MAPTA (Modeling Alliance for Systems Pharmacologies in Tauopathies). Turning imaging data information into actionable knowledge for new drug discovery" at the Human, Amyloid Imaging Conference, Miami, FL
- Nov 10, 2017
Cohen Veterans Biosciences and ISB organized the second Workshop on MAPTA (Modeling Alliance for systems Pharmacologies in TAuopathies), Washington, DC
- Oct 15-17, 2017
ISB presented work on 'A Quantitative Systems Pharmacology Approach For Predicting Pharmacological Interactions Between Antipsychotic Drugs. Validation Using Electronic Health Records" at the International Society of Pharmacometrics, Fort Lauderdale, FL.
This project is in collaboration with the BRC Nucleus, Institute of Psychiatry, King's College London describing a classifier to predict motor side-effects in schizophrenia patients on two antipsychotics in clinical practice with minimal information (only names and doses of the two drugs). This shows the superiority of Quantitative Systems Pharmacology over AI approaches, as no calibration or training set was available.
- July 26-27, 2017
ISB participated in NIA and NINDS workshop on 'Quantitative Systems Pharmacology and Drug Discovery: Filling the Gaps in Current Models of the R&D Process for Neurotherapeutics" in Washington, DC.
The purpose of this workshop was threefold:
- Assess the impact of QSP approaches on CNS drug discovery and development.
- Identify roadblocks and gaps in the application of QSP to CNS drug discovery/development.
- Identify opportunities to address roadblocks and gaps.
July 16-20, 2017
ISB presented two posters "Quantitative Systems Pharmacology understanding of beta-amyloid modulating therapies in Alzheimer's Disease" and "MAPTA, Modeling Alliance of Systems Pharmacologies in Tauopathies" at the AAIC meeting, London.
Hugo Geerts presented "BIG DATA to SMART DATA. The Role of Metabolomics in Generating Actionable Knowledge in Alzheimer�S Disease for Personalized Treatment" in the Featured Research Session.
June 12-14, 2017
ISB participated in the DoD Workshop on Drug Discovery in PTSD, Shepherdstown, WV, USA
June 11, 2017
May 26, 2017
MAPTA (Modeling Alliance for Systems Pharmacologies in Tauopathies) is the first public-private alliance exclusively focused on developing an actionable Quantitative Systems Pharmacology platform for supporting drug discovery and development in various tauopathies, ranging from Chronic Traumatic Encephalopathy, Traumatic Brain Injury over Progressive Supranuclear Palsy to Alzheimer�s Disease. Tau pathology is a very important but extremely complex target with multiple possible points of engagement, therefore building a very complex computer model integrating the current knowledge and constrained by clinical data is an interesting new approach that can mitigate some of the limitations of animal models.
Cohen Veteran�s Biosciences, a 501(c)3 non-profit research organization with a singular focus on PTSD and TBI research and dedicated to fast-tracking the development of diagnostic tests and personalized therapeutics for the millions of veterans and civilians who suffer the devastating effects of trauma on the brain has teamed up with In Silico Biosciences, a Quantitative Systems Pharmacology company focused on CNS. Supported by a world-class scientific Advisory Board and in collaboration with two top academic centers, the objective is to develop an advanced computer model that integrates substantial information ranging from the basic cell biology to clinical Tau PET imaging. More than 10 pharma companies have expressed interest in joining the alliance.
May 18-20, 2017
ISB presented "A model for Early Psychosis using Quantitative Systems Pharmacology" at the Society for Biological Psychiatry, San Diego, CA, USA
May 8-9, 2017
ISB to participate in NIMH workshop on 'Novel Approaches to Understanding the Mechanisms of the Neuropsychiatric Symptoms in Alzheimer�s and Advancing Therapy" in Washington, DC
April 22-April 23, 2017
ISB presented "FROM BIG DATA TO SMART DATA. QUANTITATIVE SYSTEMS PHARMACOLOGY OF HUMANIZED NEURONAL CIRCUITS AND THE CASE FOR RATIONAL MULTI-TARGET POLYPHARMACY IN CNS R&D" at the International Symposium on Schizophrenia, Changsha, China
March 29-April 2, 2017
ISB presented work on "SIMULATIONS OF BETA-AMYLOID CHANGES ON COGNITIVE READOUTS IN ALZHEIMER'S DISEASE USING QUANTITATIVE SYSTEMS PHARMACOLOGY" at the AD/PD Meeting, Vienna, Austria (2017 ADPD)
December 8, 2016
Hugo Geerts (ISB) presented a plenary lecture on "THE VIRTUAL HUMAN PATIENT. COMBINING BIG DATA WITH SMART DATA TO GENERATE PREDICTIVE MODELS FOR DRUG DISCOVERY AND DEVELOPMENT IN CNS DISORDERS" in the President's Symposium at the ACNP 'Fifty years of psychotherapeutic drug discovery and development : where have we been and what have we learned' (Hollywood, FL) (2016 ACNP)
November 9-11, 2016
Hugo Geerts (ISB) taught in the BrightFocus organized course on Alzheimer's Disease; San Diego, CA (2016 BrightFocus)
September 25-28, 2016
ISB presented 'A Computational Model for Psychosis in Schizophrenia' at the Lundbeck Conference on Computational Psychiatry, Copenhagen, Danemark (FENS-Lundbeck Conference)
September 22-23, 2016
Hugo Geerts (ISB) participated in the Tau Modeling Collaboration at the CNS Summit of the Cohen Veterans Biosciences in Washington, DC
September 12-13, 2016
Hugo Geerts (ISB) participated in the discussion workshop on Therapeutic Development for Nervous System Disorders in the Absence of Predictive Animal Models of Disease at the National Academy of Sciences, Washington, DC (National Academy of Sciences)
August 22-23, 2016
ISB presented 'From Big Data to Smart Data. How to generate actionable knowledge for R&D' at the Systems Biology Conference, Philadelphia, PA
July 22-26, 2016
ISB presented poster titled 'A Quantitative Systems Pharmacology Platform for Agitation and Aggression in Alzheimer's Disease' at the Alzheimer Association International Conference, Toronto, Canada (2016 AAIC)
June, 14, 2016
Hugo Geerts (ISB) has launched the Brain Health Modeling Initiative with 8 other scientists from academia, industry and patient foundations to support succesfull development of new Alzheimer's drugs using advanced modeling and simulations. Their first position paper is now in Alzheimer's and Dementia
May 16-17, 2016
Hugo Geerts (ISB) gave a podium presentation titled 'The use of Quantitative Systems Pharmacology in virtual patient CNS trial design' at the Society for Clinical Trials, Montreal, Canada (2016 SCT)
April 2-6, 2016
ISB presented poster 'Why do Clinical Trial Fail so Often in Schizonphrenia? A Quantitative Systems Pharmacology Approach to Account for the Effect of Comedications and Genotpyes' at the Schizophrenia International Research Society (SIRS), Florence, Italy (2016 SIRS)
March 6-8, 2016
Hugo Geerts (ISB) gave podium presentation titled 'The Use of Quantitative Systems Pharmacology' at the Alzheimer Drug Discovery Conference, Miami FL
February 22-26, 2016
ISB presented poster titled 'A Virtual Human Patient Computer Model of Neuronal Network Circuits in Huntington's Disease' at the CHDI Meeting on Huntington's Disease, Palm Springs, CA (2016 CDHI)
February, 17, 2016
ISB was part of panel discussion on 'Drug Repurposing' and presented poster 'Repurposing Drugs for Agitation and Aggression in Alzheimer's Disease Using a Quantitative Systems Pharmacology Platform' at the International Society for CNS Trial Methodologies, Washington, DC (2016 ISCTM Spring Meeting ).
January 20, 2016
ISB presented their platform on Alzheimer pathology at Imperial College London.
January 19-21, 2016
ISB presented 'From Big Data to Smart Data in CNS disease. How to address the fundamental limitations of traditional bio-informatics approaches' at the Life Sciences R&D Big Data Leaders Forum, London, UK (2016 Big Data Life Sciences meeting).
November 12, 2015
ISB presented their platform on Alzheimer pathology in the Deutsche Zentrum for Neurodegenerative Erkrankungen (Bonn, Germany).
November 5-7, 2015
ISB presented 'Clinical combination trials with amyloid modulating agents. A Quantitative Systems Pharmacology perspective' at the Conference on Clinical Trials in Alzheimer's Disease, Barcelona, Spain (2015 CTAD meeting).
Oct 10, 2015
ISB presented their platform for supporting CNS Clinical Trial Design titled 'How Quantitative Systems Pharmacology can support CNS Pharmaceutical R&D' at CNS Summit, Boca Raton, FL (2015 CNS Summit meeting).
October 4-7, 2015
Presented 'From Big Data to Smart Data. How Quantitative Systems Pharmacology can support CNS Pharmaceutical R&D' at the International Society for Pharmacometrics, Arlington, VA (2015 ACOP meeting).
September 23-25, 2015
Presented 'A practical solution for supporting a rationally designed mult-target GPCR drug discovery project for CNS Disorders' at the 2015 Discovery on Target meeting.
Aug 6, 2015
ISB was invited to the Reagon-Udall Foundation and FDA sponsored workshop on 'Pharmacological Mechanism-Based Drug Safety Prediction: Integrated Computational Approaches for Problem Solving of Systems Comprised of Multiple Levels of Biological Organization, from Drug Exposure to Clinical Phenotype", held at FDA. The Reagan-Udall Foundation provides support for improving Regulatory Sciences.
ISB discussed their platform for predicting CNS-related - reversible, but quality of life modifying - side-effects such as involuntary movements and cognitive worsening.
July 18-23, 2015
Chaired session on Clinical trials in AD and presented symposium 'Virtual Human Patient Trials. Studying anti-amyloid immunotherapies' at the Alzheimer Association International Congress (AAIC), Washington, DC (2015 AAIC meeting).
June 17-18, 2015
Invited to the Religious Order Study and the Rush Alzheimer's Disease Center work-group to explore mechanism-based modeling approaches in order to generate actionable knowledge for Alzheimer's Disease drug discovery & development
June 15, 2015
Quantitative Systems Pharmacology and In Silico Biosciences featured in Life Science Leader June 2015 edition "Moving Human clinical Trial design into the 21st Century"
Life Science Leader
June 12, 2015
Symposium presentation by Hugo Geerts 'Reconstructing CNS Disease complexity through Quantitative Systems Pharmacology' at the Orion BioNetwork Symposium, Cambridge MA - "Convergence through complexity"
2015 Orion Bionetwork Conference
May 26, 2015
Poster presentation 'Amyloid Dynamics and effect on cognition in AD. A Quantitative Systems Pharmacology study' at New York Academy of Science, New York NY "Quantitative Systems Pharmacology"
April 12, 2015
Editorial Board member of Alzheimer's & Dementia: Translational Research & Clinical Interventions (editor-in-chief Lon Schneider)
April 5, 2015
Invited to the work-group preparing ADNI-III proposal to explore mechanism-based modeling approaches in order to generate actionable knowledge for drug discovery & development
March 30, 2015
Symposium presentation by Hugo Geerts 'Galantamine-Memantine combination therapy as studied by Quantitative Systems Pharmacology for Cognitive Impairment in Schizophrenia' at the International Congress on Schizophrenia Research, Colorado Springs, CO.
March 20, 2015
Symposium presentation by Hugo Geerts 'Reconstructing the complexity of Alzheimer's disease by using Quantitative Systems Pharmacology as a possible alternative to preclinical animal models' at the AD-PD Meeting, Nice, France.
February 12, 2015
Active member of work-group at NIA AD Summit on computational approaches for Alzheimer Drug discovery & Development
January 19, 2015
Poster 'A Quantitative Systems Pharmacology Study of the Combination of Galantamine and Memantine for Cognitive Impairment in Schizophrenia' presented at International Conference on Imaging Genetics, Irvine, CA.
December 15, 2014
Co-founded the Brain Disorders Modeling Initiative workgroup on "going from Big Data to Smart Data" with the aim of developing the next-generation predictive modeling approaches that generate 'actionable knowledge' for drug discovery and development in Alzheimer's disease
November 21, 2014
Poster 'Not all comedications are the same. Careful consideration of the impact of different comedications can substantially improve success in CNS clinical trials' presented at Clinical Trial in Alzheimer's Disease, Fall Meeting, Philadelphia, PA.
Poster 'New insights into human brain amyloid kinetics from a humanized computer modeling study' presented at Society for Neuroscience, Washington DC.
October 9, 2014
Presentation by Hugo Geerts 'Using Quantitative Systems Pharmacology for supporting rationally designed multi-target discovery projects in CNS R&D' at the 2014 Drug Discovery on Target Meeting, Boston, MA.
June 25, 2014
Presentation by Hugo Geerts 'Quantitative Systems Pharmacology to Support Alzheimer R&D' at the 2014 EuroScicon Alzheimer's Congress London, UK.
May 30, 2014
Participation in the Workgroup 'From Big Data to Smart Data in Alzheimer's Disease' sponsored by the Alzheimer Association and AD2020 Washington, DC.
April 30, 2014
Presentation by Hugo Geerts 'The Human Avatar: Quantitative Systems Pharmacology to Support Physician Decision Making in Neurology and Psychiatry' at the Bio-IT World Congress in the program 'Systems Pharmacology', Boston, MA.
October 17, 2013
Speaker at the Biotarget 3th World Drug Discovery Virtual Conference on 'De-risking CNS R&D by using Quantitative Systems Pharmacology', Luxembourg.
October 14-16, 2013
Speaker at the First European Translational Medicine Summit on 'De-risking CNS R&D by using Quantitative Systems Pharmacology', Luxembourg.
July 16-19, 2013
Start of the PIA on 'From Big data to Smart Data in Alzheimer's disease' at the Alzheimer Association Meeting in Boston, MA.
May 28-30, 2013
Active participation in the expert panel on Combination Therapies in Alzheimer's Disease, Washington, DC.
May 13, 2013
Presentation by Hugo Geerts 'Using Quantitative Systems Pharmacology for Failure Analysis of Dimebon in Alzheimer's Disease' at the American Conference of Pyschometrics, Fort Lauderdale, FL.
May 1, 2013
Drugs in Clinical Trials link on SchizophreniaForum.org website officially active; searchable database of ongoing clinical development projects in schizophrenia.
April 28-29, 2013
Active participation in 'From Big Data to Smart Data' at the Banbury Conference for Neuropsychiatry.
Dec 11, 2012
Patent US 8.332.158 on �Method and apparatus for computer modeling of the interaction between and among cortical and subcortical areas in the human brain for the purpose of predicting the effect of drugs in psychiatric and cognitive diseases� was granted to ISB.
Dec 1, 2012
ISB arranges for providing in-kind services to the Alzheimer Drug Discovery Foundation. ISB will perform a complimentary first-pass analysis of off-target pharmacology for a clinical candidate and offers discounted servcies for follow-up project support to grantees of ADDF.
October 25-26, 2012
Presentation 'Using Quantitative Systems Pharmacology for De-Risking Projects in CNS R&D' at the CGT Meeting on PK/PD Congress, Philadelphia, PA.
July 15-18, 2012
Poster on 'Failure analysis on Dimebon using quantitative Systems Pharmacology approach'at the AAIC Alzheimer meeting in Vancouver, Canada.
Poster on 'Systems Pharmacology Modeling in 5-HT4: Prediction and outcome of a clinical scopolamine impairment trial and further application to Alzheimer's Disease pathology'at the AAIC Alzheimer meeting in Vancouver, Canada.
June 7, 2012
Presentation by Hugo Geerts 'From gene to function : Understanding Human Variability using Mechanistic Disease Modeling and Imaginomics' at the Bio-IT Asia Congress in the program 'Systems Biology', Singapore.
May 31-June 2, 2012
Presentation by Patrick Roberts on modeling schizophrenia and Alzheimer's Disease at the Fields symposium on Mathematical Modeling in Neurological Diseases, Toronto, Canada.
April 30, 2012
Patent US 8,150,629 B2, granted to ISB �Method and apparatus for computer modeling of the interaction between cortical and subcortical areas in the human brain�.
April 25, 2012
Presentation by Hugo Geerts 'From gene to function : Understanding Human Variability using Mechanistic Disease Modeling and Imaginomics' at the Bio-IT World Congress in the program 'Systems and Multiscale Biology', Boston, MA.
March 28-29, 2012
Panel Discussion of Quantitative Systems Pharmacology in the Institute of Medicine workshop on 'Improving Animal Models for CNS Diseases', Washington DC.
December 14, 2011
Presentation by Hugo Geerts at the CBI Congress 'Drug R&D in Alzheimer's Disease', Arlington, VA.
October 2, 2011
Presentation by Hugo Geerts at the CIT Asian Drug Discovery Congress 'Predictive Technologies', Shenzhen, China.
April 24, 2011
Presentation by Hugo Geerts at the Bio-IT World Congress in the program 'Predictive Technologies', Boston, MA.
October 10, 2010
In Silico Biosciences is a winner of the Innovation Corridor Award at the PA Biotech Convention, Philadelphia, PA.
August 23, 2010
Hugo Geerts, COO, was a panelist on 'Easing the Drug Discovery Bottleneck', Philadelphia, PA.
June 29, 2010
Hugo Geerts, COO gave KeyNote Lecture at Neurotalk 2010, Singapore.
April 22, 2010
Presentation at the Bio-IT World Congress in the program 'Predictive Technologies', Boston.
December 17, 2009
Hugo Geerts, COO, has presented a Webinar on the Alzforum and the SchizophreniaForum on "From Mice to Men. Bridging the translational Disconnect in CNS R&D".
October 14, 2009
Hugo Geerts, COO, has presented at the IBC 'Drug repositioning Summit' on "Using Computational Neuropharmacology to Support Repositioning Strategies in CNS Disorders".
April 25, 2009
The company has been awarded a Michael J Fox Foundation Rapid Innovation Award for a project on "Exploring serotonergic cortical targets for treatment of Parkinson's disease using a mathematical disease model".
The project runs for a year and is intended to 'screen' the pharmacology of the Prestwick library in the company's EPS liability module that has been converted into a Parkinson's disease model.